87151-66-4

Usage

Uses

Used in Pharmaceutical Industry:
3-(1,4-Cyclohexadien-1-yl)-1-p is used as a precursor for the synthesis of various pharmaceuticals, contributing to the development of new drugs and medications.
Used in Agrochemical Industry:
In the agrochemical sector, 3-(1,4-Cyclohexadien-1-yl)-1-p serves as a precursor for the production of agrochemicals, aiding in the creation of effective pest control and crop protection solutions.
Used in Fragrance Industry:
3-(1,4-Cyclohexadien-1-yl)-1-p is utilized as a precursor in the fragrance industry, enabling the synthesis of diverse scents and aromas for various applications.
Used as a Reagent in Organic Chemistry:
3-(1,4-Cyclohexadien-1-yl)-1-p is employed as a reagent in organic chemistry reactions, facilitating various chemical processes and transformations due to its high reactivity.

Upstream product

• 122-97-4 3-Phenyl-1-propanol 
• 104-54-1 3-Phenylpropenol 
• 501-52-0 3-Phenylpropionic acid 
• 85029-28-3 3-(1,4-cyclohexadien-1-yl)-1-propanoic acid 

Downstream Products

• 851051-41-7 N-(1R,2R)-[2-(3-cyclohexa-1,4-dienyl-propylamino)-1,2-diphenyl-ethyl]-4-methyl-benzene sulphonamide 
• 1381868-52-5 C₂₉H₂₈O₂ 
• 1245811-48-6 tethered (S,S)-MsDPEN 
• 851051-44-0 N-[(1R,2R)-2-(3-cyclohexa-1,4-dienylpropylamino)-1,2-diphenylethyl]-4-methylbenzenesulfonamide 
• 1245811-44-2 C₁₈H₂₆N₂O₂S 
• 87151-63-1 1-Oxaspiro<4.5>dec-7-ene 
• 1352399-58-6 1-(4-sulfonatobutyl)-1,4-cyclohexadiene sodium salt 
• 1352399-56-4 1-(3-bromopropyl)-1,4-cyclohexadiene 
• 663603-28-9 3-(cyclohexa-1,4-dienyl)propionaldehyde 

Relevant academic research and scientific papers

Osmium(ii) tethered half-sandwich complexes: pH-dependent aqueous speciation and transfer hydrogenation in cells

Aquation is often acknowledged as a necessary step for metallodrug activity inside the cell. Hemilabile ligands can be used for reversible metallodrug activation. We report a new family of osmium(ii) arene complexes of formula [Os(η6-C6H5(CH2)3OH)(XY)Cl]+/0(1-13) bearing the hemilabile η6-bound arene 3-phenylpropanol, where XY is a neutral N,N or an anionic N,O?bidentate chelating ligand. Os-Cl bond cleavage in water leads to the formation of the hydroxido/aqua adduct, Os-OH(H). In spite of being considered inert, the hydroxido adduct unexpectedly triggers rapid tether ring formation by attachment of the pendant alcohol-oxygen to the osmium centre, resulting in the alkoxy tethered complex [Os(η6-arene-O-κ1)(XY)]n+. Complexes1C-13Cof formula [Os(η6:κ1-C6H5(CH2)3OH/O)(XY)]+are fully characterised, including the X-ray structure of cation3C. Tether-ring formation is reversible and pH dependent. Osmium complexes bearing picolinate N,O-chelates (9-12) catalyse the hydrogenation of pyruvate to lactate. Intracellular lactate production upon co-incubation of complex11(XY = 4-Me-picolinate) with formate has been quantified inside MDA-MB-231 and MCF7 breast cancer cells. The tether Os-arene complexes presented here can be exploited for the intracellular conversion of metabolites that are essential in the intricate metabolism of the cancer cell.

Organocatalyzed Birch Reduction Driven by Visible Light

The Birch reduction is a powerful synthetic methodology that uses solvated electrons to convert inert arenes to 1,4-cyclohexadienes - valuable intermediates for building molecular complexity. Birch reductions traditionally employ alkali metals dissolved in ammonia to produce a solvated electron for the reduction of unactivated arenes such as benzene (Ered -3.42 V vs SCE). Photoredox catalysts have been gaining popularity in highly reducing applications, but none have been reported to demonstrate reduction potentials powerful enough to reduce benzene. Here, we introduce benzo[ghi]perylene imides as new organic photoredox catalysts for Birch reductions performed at ambient temperature and driven by visible light from commercially available LEDs. Using low catalyst loadings (1 mol percent), benzene and other functionalized arenes were selectively transformed to 1,4-cyclohexadienes in moderate to good yields in a completely metal-free reaction. Mechanistic studies support that this unprecedented visible-light-induced reactivity is enabled by the ability of the organic photoredox catalyst to harness the energy from two visible-light photons to affect a single, high-energy chemical transformation.

Ansa-Ruthenium(II) Complexes of R2NSO2DPEN-(CH2)n(η6-Aryl) Conjugate Ligands for Asymmetric Transfer Hydrogenation of Aryl Ketones

New 3rd generation designer ansa-ruthenium(II) complexes featuring N,C-alkylene-tethered N,N-dialkylsulfamoyl-DPEN/η6-arene ligands, exhibited good catalytic performance in the asymmetric transfer hydrogenation (ATH) of various classes of (het)aryl ketones in formic acid/triethylamine mixture. In particular, benzo-fused cyclic ketones furnished 98 to >99.9% ee using a low catalyst loading.

PROCESS FOR HYDROGENATING KETONES IN THE PRESENCE OF RU(II) CATALYSTS

The present invention relates to a process for hydrogenating a substrate comprising a carbon-heteroatom double bond, the process comprising the step of reacting the substrate with hydrogen gas in the presence of a hydrogenation catalyst, wherein the hydro

A New Class of "Tethered" Ruthenium(II) Catalyst for Asymmetric Transfer Hydrogenation Reactions

Ruthenium dimer 4 is converted directly to monomeric asymmetric transfer hydrogenation catalyst 2 under the conditions employed for ketone reduction. Using 0.25 mol % of either 4 or 0.5 mol % of 2 in formic acid/triethylamine, it is possible to achieve ketone reduction in quantitative conversion and with ee's as high as 98%. Complex 2 is a robust "single-reagent" catalyst which offers significant scope for modification toward specific substrates. The synthesis and applications of an analogous complex derived from (1R,2S)-norephedrine are also described. Copyright

Analgesic 1-oxa-, aza- and thia-spirocyclic compounds

Mono-Oxa-, thiaspirocyclic-benzene-acetamide and -benzamide compounds of the formula STR1 wherein p, n, m, A, E, R, R1, R2, X, Y and Z are as defined in the specification, e.g., (±)-(5α,7α,9β)-3,4-dichloro-N-methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]benzeneacetamide, and the pharmacologically acceptable salts thereof, are useful as analgesic compounds having low physical dependence liability, compared to morphine and methodone, and low dysphoria side effects. Some of these compounds have potent analgesic activity when administered orally, and some have low CNS sedative side effects. Pharmaceutical compositions and methods for using these compounds as analgesics are disclosed. Processes for preparing this class of compounds are also disclosed.